Q2 2012 Results (Rigel) - Aug 7, 2012 - Anticipated initiation of P2 trial for discoid lupus this month
Anticipated new P2 trial • Lupus
|
|
R 333
--
Rigel reported total operating expenses of approximately $26.4 million in the second quarter of 2012, compared to approximately $22.0 million for the same period in 2011. The increase in operating expenses was primarily due to increased costs related to R343, Rigel's inhaled SYK inhibitor program for asthma and R333, a topical JAK/SYK inhibitor program for discoid lupus. Both of these programs are expected to begin Phase 2 clinical trials this month.
---
(IR 5)
|